Chlapanidas Theodora, Perteghella Sara, Leoni Flavio, Faragò Silvio, Marazzi Mario, Rossi Daniela, Martino Emanuela, Gaggeri Raffaella, Collina Simona
Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section (MCPTS), Cell Delivery System Laboratory, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
Italfarmaco Research Center, Via dei Lavoratori 54, 20092 Cinisello Balsamo, Italy.
Int J Mol Sci. 2014 Aug 6;15(8):13624-36. doi: 10.3390/ijms150813624.
This study aims to evaluate the effect of combined use of the racemic flavanone Naringenin (NRG) and the protein sericin as TNF-α blockers. Sericin (SMs) and (R/S) NRG-loaded Sericin (SNRGMs) microparticles were prepared by spray-drying, characterized in terms of morphology and particle size distribution, and encapsulation efficiency was determined. Concerning morphology and particle size distribution of microparticles, results indicated that they were not affected by the presence of NRG. The encapsulation efficiency was almost quantitative (93%), thus proving that sericin can be advantageously loaded with (R/S) NRG. Biological evaluation of (R/S) NRG, SMs and SNRGMs was then performed in lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells (hPBMC). SNRGMs resulted cytotoxic at the higher dose used (200 μg/mL) and the effect was greater than (R/S) NRG alone. Moreover, even if sericin alone was not effective in suppressing LPS-induced serum TNF-α levels, SNRGMs loaded with 9.3% of (R/S) NRG were significantly more potent than (R/S) NRG alone. In summary, this study provides the proof of concept that sericin-based microspheres loaded with TNF-α-blockers could contribute to the down regulation of the cytokine and represents the starting point for the development of new topical formulations for the treatment of middle-stage psoriasis.
本研究旨在评估消旋黄酮柚皮素(NRG)与蛋白质丝胶蛋白联合使用作为肿瘤坏死因子-α(TNF-α)阻滞剂的效果。通过喷雾干燥制备了丝胶蛋白(SMs)以及负载(R/S)NRG的丝胶蛋白(SNRGMs)微粒,对其形态和粒径分布进行了表征,并测定了包封效率。关于微粒的形态和粒径分布,结果表明它们不受NRG存在的影响。包封效率几乎达到定量水平(93%),从而证明丝胶蛋白能够有效地负载(R/S)NRG。随后在脂多糖(LPS)刺激的人外周血单核细胞(hPBMC)中对(R/S)NRG、SMs和SNRGMs进行了生物学评估。SNRGMs在所用的较高剂量(200μg/mL)下具有细胞毒性,且效果大于单独使用(R/S)NRG。此外,即使单独的丝胶蛋白在抑制LPS诱导的血清TNF-α水平方面无效,但负载9.3%(R/S)NRG的SNRGMs比单独的(R/S)NRG显著更有效。总之,本研究提供了概念验证,即负载TNF-α阻滞剂的丝胶蛋白基微球有助于细胞因子的下调,并代表了开发用于治疗中期银屑病的新型局部制剂的起点。